Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations
23 juin 2023 16h30 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)
19 juin 2023 18h54 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
12 juin 2019 08h00 HE
|
Mersana Therapeutics, Inc.
Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE...
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
27 nov. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
13 nov. 2018 07h00 HE
|
Mersana Therapeutics, Inc.
XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation Enrollment Resumed Mersana to Present New Data on Dolasynthen and...
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
12 nov. 2018 09h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
12 nov. 2018 07h00 HE
|
Mersana Therapeutics, Inc.
Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage...
Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522
17 sept. 2018 07h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
30 août 2018 16h01 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates
14 août 2018 16h20 HE
|
Mersana Therapeutics, Inc.
Response to the FDA Partial Clinical Hold Submitted This Week Strong Balance Sheet with a cash position of $97M to close Q2 CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mersana...